ArticleCardio-oncology (London, England)2026
Midodrine to facilitate cardioprotective therapy in hypotensive HER2-positive breast cancer patients with cancer-therapy-related cardiac dysfunction-multicenter case experience.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHER2-targeted therapies significantly improve outcomes in HER2-positive breast cancer but are associated with cancer therapy-related cardiac dysfunction (CTRCD), which may necessitate interruption of oncologic treatment. Hypotension, which is not uncommon in patients with cancer, may limit the use of guideline-directed medical therapy (GDMT) required for left ventricular (LV) recovery, and no approved strategy exists to safely augment blood pressure in this setting. CASE PRESENTATION: We report two cases of hypotensive breast cancer patients who developed CTRCD during HER2-targeted therapy and were unable to tolerate GDMT due to symptomatic hypotension. In both cases, initiation and titration of midodrine enabled stabilization of blood pressure, facilitation of cardioprotective therapy with beta-blockers and/or sodium-glucose cotransporter-2 inhibitors, and subsequent recovery of LV systolic function. This strategy allowed continuation or reinitiation of life-prolonging HER2-directed therapy without worsening heart failure or significant adverse effects. DISCUSSION AND
conclusionsMidodrine may serve as a practical hemodynamic adjunct to enable guideline-directed cardioprotective therapy in selected hypotensive patients with HER2 therapy-related cardiomyopathy. These cases illustrate the feasibility of blood pressure augmentation as a strategy to facilitate cardiac recovery while preserving access to essential oncologic therapy. They do not establish efficacy or safety, and prospective studies with systematic assessment and predefined endpoints are warranted to define patient selection and long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.